This article is more than 5 years old. Information may no longer be current.
Verkazia approved in Scotland for vernal keratoconjunctivitis in children, adolescents
Click Here to Manage Email Alerts
The Scottish Medicines Consortium has approved Verkazia eye drop emulsion for the treatment of vernal keratoconjunctivitis in children from 4 years of age and adolescents, Santen UK Limited announced in a press release.
Verkazia, which contains 0.1% cyclosporine, targets the underlying cause of inflammation at the surface of the eye.
“The SMC decision to approve Verkazia marks a real turning point for everyone affected by this distressing condition in Scotland, providing, at last, an effective, licensed option which can be used to sustainably control the signs and symptoms of severe VKC,” Atiya Kenworthy, PhD, of Santen medical affairs, said in the release. “We have worked hard in collaboration with the SMC and are delighted to put into practice Santen’s commitment to bring innovative eye medicines for real unmet medical needs.”
In July, the European Commission approved Verkazia as an orphan medicinal product for severe vernal keratoconjunctivitis.